Trending...
- MainConcept Easy Video API Extends Full Transcoding to Arm and NETINT VPUs
- Black Women Living With, and Impacted by, HIV Express Gratitude, Grief, Joy, and Resilience
- New Online Board Game Sin of Angels Lets Outlaw Gangs Battle for LA Solo or With Friends
* HMBD ~ Hummingbird Bioscience, a data-driven precision biotherapeutics company, announced a Trials in Progress poster presentation for HMBD-002, a unique anti-VISTA antibody, at the American Society of Clinical Oncology (ASCO) Annual Meeting. The poster will summarize the Phase 1 clinical trial design for HMBD-002.
HMBD-002 is a non-depleting, high-affinity anti-VISTA antibody that possesses key design features enabling robust anti-tumor activity in preclinical models. It is being assessed in a Phase 1 study to determine the recommended Phase 2 dose as a monotherapy and in combination with pembrolizumab. Monotherapy escalation cohorts 1-4 have been completed without dose-limiting toxicities and the trial is currently enrolling cohort 5. Combination escalation is projected to begin in the second half of 2023.
More on illi News
Jerome Boyd-Kirkup, Ph.D., Hummingbird Bioscience's Chief Scientific Officer said: "VISTA's complex biology makes it a hard-to-drug target, yet we have shown in our preclinical studies that HMBD-002 has potent anti-tumor activity with its unique mechanism of action. In this poster at ASCO, we will display the progress that HMBD-002 has made in Phase 1 trials."
The poster session track is Developmental Therapeutics—Immunotherapy and will be held on June 3rd from 8:00 AM – 11:00 AM CDT at Hall A with Poster Board Number 505b. It is expected that Hummingbird Bioscience will discuss longer term clinical development plans and combination strategies with the wider immuno-oncology community at ASCO.
HMBD-002 has potential to be an important new therapy for VISTA expressing cancers including triple negative breast cancer and non small cell lung cancer.
HMBD-002 is a non-depleting, high-affinity anti-VISTA antibody that possesses key design features enabling robust anti-tumor activity in preclinical models. It is being assessed in a Phase 1 study to determine the recommended Phase 2 dose as a monotherapy and in combination with pembrolizumab. Monotherapy escalation cohorts 1-4 have been completed without dose-limiting toxicities and the trial is currently enrolling cohort 5. Combination escalation is projected to begin in the second half of 2023.
More on illi News
- Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
- Chicago Creator Aaron Devere Unveils GOOBZ'D™, an Original Animated and Collectible Universe
- Kerri Lawless Introduces New Home-Selling Option for Local Homeowners
- FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
- Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
Jerome Boyd-Kirkup, Ph.D., Hummingbird Bioscience's Chief Scientific Officer said: "VISTA's complex biology makes it a hard-to-drug target, yet we have shown in our preclinical studies that HMBD-002 has potent anti-tumor activity with its unique mechanism of action. In this poster at ASCO, we will display the progress that HMBD-002 has made in Phase 1 trials."
The poster session track is Developmental Therapeutics—Immunotherapy and will be held on June 3rd from 8:00 AM – 11:00 AM CDT at Hall A with Poster Board Number 505b. It is expected that Hummingbird Bioscience will discuss longer term clinical development plans and combination strategies with the wider immuno-oncology community at ASCO.
HMBD-002 has potential to be an important new therapy for VISTA expressing cancers including triple negative breast cancer and non small cell lung cancer.
Filed Under: Business
0 Comments
Latest on illi News
- CodeAutomation Expands U.S. Footprint to Meet Growing Demand for AI and Automation Solutions
- HydroExcavation.com Relaunches With Exclusive Local Service Areas and Dedicated Hydrovac Manufacturer Directory
- Sky Quarry Enters a Powerful New Chapter: Refinery Restart Emminent, Nevada Oil Initiative and Visibility Put (NAS DAQ: SKYQ) in the Spotlight
- OneVizion Launches Vera AI, Bringing Connected Operational Context to Infrastructure Teams
- P-Wave Press Announces Pushing the Wave 2025 by L.A. Davenport
- DONGSHENG Titanium Recycling: Promoting a Closed-Loop Cycle for High-End Titanium Materials
- Chicago: Mayor Brandon Johnson, Lawndale Christian Health Center Celebrate Grand Opening of New Family and Senior Health Center
- French Camp Academy Releases New Video Inviting Individuals to Consider a Life of Service
- LET US READ Documentary on Dyslexia and Literacy to Screen at TCL Chinese 6 in Hollywood
- Quinceañera Expo Chicago November 1, 2026, Bringing Inspiration, Fashion and Quinceañera Plan
- Defense & Space Strategy Strengthens as New Leadership Builds on NASA Results and Expanding Multi-Orbit Opportunities for Ascent Solar Technologies
- Chicago: Mayor Brandon Johnson, R2 Development Celebrate Grand Opening of The Bellwether, First Completed Office to Residential Conversion in The Loop
- Chicago: Mayor Brandon Johnson, DFSS Launch Disaster Relief Assistance Program for People Who Faced Financial Hardship Due to Severe Storms in 2023 and 2024
- Mayor Brandon Johnson, City Officials, and Community Leaders Outline Plans For Chicago's 2026 Mexican Independence Day Celebrations
- STS Capital Partners is pleased to announce the appointment of Barry Brown as Vice President, Business Development
- Qscription Technologies and NEOPATHOLOGY CORP. Sign MOU to Bring FDA-Cleared Lung Imaging AI into U.S. Clinical Practice
- Howe & Hutton Closes; Jonathan T. Howe Transitions to Association Law Group LLC
- Naperville: Police Investigate Report of Gunshots
- Aerostratospheric Adds xAirship and Other Shop Test Units to Its xPrototypes Bench
- Firebox Encapsulator Introduces a New Approach to Fireplace Restoration